EUVIMEDEUVIMED entdecken
Crossref

Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo

Jiahui Zhu, Ran Wei, Guang Hu, Hui Wang, Wenbin Wang, Haiqiang Wang, Jidan Huang, Yu Wang, Yujing Li iD, Huan Meng iD

Small · 2024

DOI: 10.1002/smll.202310340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2024. Verfasst von Jiahui Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscien…. Hauptthemen laut MEDLINE: Chondrosarcoma, Nanocomposites, Drug Resistance, Neoplasm, Hydrogels. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Institute of Technology Research Fund Program for Young Scholars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chondrosarcoma(CS), a prevalent primary malignant bone tumor, frequently exhibits chemotherapy resistance attributed to upregulated anti‐apoptosis pathways such as the Bcl‐2 family. In this manuscript, a new strategy is presented to augment chemosensitivity and mitigate systemic toxicity by harnessing a nano‐enabled drug delivery hydrogel platform. The platform utilizes “PLGA‐PEG‐PLGA”, an amphiphilic triblock copolymer combining hydrophilic polyethylene glycol (PEG) and hydrophobic polylactide glycolide (PLGA) blocks, renowned for its properties conducive to crafting a biodegradable, temperature‐sensitive hydrogel. This platform is tailored to encapsulate a ratiometrically designed dual‐loaded liposomes containing a first‐line chemo option for CS, Doxorubicin (Dox), plus a calculated amount of small molecule inhibitor for anti‐apoptotic Bcl‐2 pathway, ABT‐737. In vitro and in vivo evaluations demonstrate successful Bcl‐2 suppression, resulting in the restoration of Dox sensitivity, evident through impeded tumor growth and amplified necrosis rates at the tumor site. This delivery system showcases remarkable thermal responsiveness, injectability, and biodegradability, all finely aligned with the clinical demands of CS treatment. Collectively, this study introduces a transformative avenue for tackling drug resistance in CS chemotherapy, offering significant clinical potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrosarcomaNanocompositesDrug Resistance, NeoplasmHydrogelsDoxorubicinDrug Delivery SystemsAnimalsHumansCell Line, TumorTemperaturePolyethylene GlycolsMice

Stichwörter der Autor:innen

Bcl‐2chemotherapy resistancechondrosarcomacombination therapyhydrogel

Substanzen

HydrogelsDoxorubicinPolyethylene Glycols

Autor:innen und Institutionen

  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China.
  • School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, 400054, China.
  • Musculoskeletal Tumor Center, Beijing Key Laboratory of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, 100044, China.
  • School of Medical Technology, Beijing Institute of Technology, Beijing, 100081, China.
  • Academy of Medical Sciences, The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, 450052, China.
  • USTC Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230000, China.

ORCID-Profile: Yujing Li, Huan Meng

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Beijing Institute of Technology Research Fund Program for Young Scholars
  • Peking University People's Hospital Scientific Research Development Funds
  • Chinese Academy of Sciences
  • CAS Project for Young Scientists in Basic Research

Zitieren

APA

Zhu, J., Wei, R., Hu, G., Wang, H., Wang, W., Wang, H., Huang, J., Wang, Y., Li, Y., & Meng, H. (2024). Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo. Small. https://doi.org/10.1002/smll.202310340

Vancouver

Zhu J, Wei R, Hu G, Wang H, Wang W, Wang H, et al. Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo. Small. 2024. doi:10.1002/smll.202310340

BibTeX
@article{Zhu2024,
  author = {Zhu, Jiahui and Wei, Ran and Hu, Guang and Wang, Hui and Wang, Wenbin and Wang, Haiqiang and Huang, Jidan and Wang, Yu and Li, Yujing and Meng, Huan},
  title = {Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric Drug Delivery to Treat Drug Resistant Chondrosarcoma In Vivo},
  journal = {Small},
  year = {2024},
  doi = {10.1002/smll.202310340}
}
Kostenlos starten →